Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Multi-omics profiling reveals an immunosuppressive microenvironment and PRL-3 as a therapeutic target in myeloma extramedullary disease

View Full Paper
Ask AI
Bookmark
Share

Authors

HHHe Huang

Discussion

Loading...

Member takes

Overview

Single-cell analysis reveals hypoxia-induced macrophages may support aggressive myeloma behavior, implying strategies targeting therapeutic outcomes.

Key Points

  • Therapeutic targets were identified in the immunosuppressive tumor microenvironment affecting myeloma cells.
  • Analysis revealed significant macrophage involvement in supporting hypoxic conditions within extramedullary disease.
  • Single-cell RNA sequencing provided insights into cellular interactions and identified key pathways impacting myeloma aggression.
  • Targeting therapeutic mechanisms has potential for improving outcomes in patients with aggressive myeloma presentations.

Cite This Study

He Huang (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6c8https://doi.org/10.1182/blood-2025-5710
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Relationship between myeloma cell genomic alternations and tumor immune microenvironment in bone-related extramedullary disease of newly diagnosed multiple myeloma2025
  2. 2Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy2025
  3. 3Single-cell transcriptomics reveals proliferative, immune-evasive, and bone marrow–independent transcriptional programs in extramedullary multiple myeloma.2025
  4. 4Single-cell profiling uncovers PTPRG-driven stemness in malignant plasma cells and signatures of treatment failure in multiple myeloma2025
  5. 5Genomic and transcriptomic signatures of extramedullary multiple myeloma reveal possible drivers of therapeutic resistance2025